Patrick: An Introduction to Medicinal Chemistry 4e
Chapter 07
Further reading
Flower, R. J. (2003) The development of COX 2 inhibitors. Nature Reviews Drug Discovery, 2, 179-191 [DOI: 10.1038/nrd1034] [PubMed: 12612644].
Maryanoff, B. E., and Maryanoff, C. A. (eds.). (1992) Some thoughts on enzyme inhibition and the quiescent affinity label concept. Advances in Medicinal Chemistry, 1, 235-261.
Mitchell, J. A., and Warner, T. D. (2006) COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nature Reviews Drug Discovery, 5, 75-86 [DOI: 10.1038/nrd1929] [PubMed: 16485347].
Navia, M. A., and Murcko, M. A. (1992) Use of structural information in drug design. Current Opinion in Structural Biology, 2, 202-216 [DOI: 10.1016/0959-440X(92)90147-Y].
Siragy, H. M., Kar, S., and Kirkpatrick, P. (2007). Nature Reviews Drug Discovery, 6, 779-780 [DOI: 10.1038/nrd2421].
Teague, S. J. (2003) Implications of protein flexibility for drug discovery. Nature Reviews Drug Discovery, 2, 527-541 [DOI: 10.1038/nrd1129] [PubMed: 12838268].


